MBX Biosciences rises after mid-stage trial win for hormone disorder drug

ReutersSep 22, 2025 12:36 PM

Shares of drug developer MBX Biosciences MBX.O surge 84% to $18.5 in premarket trading

MBX says its once-weekly experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

In 12-week study, 63% of patients on canvuparatide kept calcium in normal range without needing active vitamin D or more than 600 mg of daily calcium supplements, compared with 31% on placebo, difference of which was statically significant

The drug was well tolerated with no serious adverse events, company says

MBX plans to start late-stage trial in 2026

As of last close, MBX stock was down 45.7% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Why SanDisk Stock Could Soar to $4,000?

If SanDisk continues along its path and actually achieves the consensus estimate of $168 in earnings per share in one year, a P/E multiple of 22 — which is a rather conservative estimate of the S&P 500 average — would imply a stock price of close to $4,000.

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

TradingKey - AI chipmaker Cerebras is reportedly planning to list on Nasdaq on May 14 under the ticker symbol “CBRS.” The IPO is expected to be the largest in the U.S. this year, placing Nvidia’s (NVDA) strongest challenger in the AI computing space officially under the capital market spotlight.

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

TradingKey — Intel (INTC) shares surged on Friday following reports of a preliminary cooperation agreement with Apple (AAPL). The stock’s intraday gain briefly exceeded 13% before closing up 13.96%, with its market capitalization jumping to $627.8 billion.

Trump’s Shifting Stance Deadlocks US-Iran Talks, Citi Maintains $120 Brent Target

TradingKey - On May 8 (ET), Citi stated that oil prices could rise further if US-Iran negotiations remain deadlocked, maintaining its forecast that Brent crude will reach $120 over the next three months.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools